3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Triple Negative Breast Neoplasms
7
Breast Neoplasms
6
Lung Neoplasms
5
Ovarian Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Neoplasms
2
Medulloblastoma
2
Fallopian Tube Neoplasms
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Thymic epithelial tumor
1
Thrombocythemia, Essential
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Squamous NSCLC
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Retinoblastoma
1
Recurrence
1
Primary Myelofibrosis
1
Primary Malignant Neoplasm of Ovary
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
fosbretabulin
1
combretastatin
1
Sodium Iodide
1
Paclitaxel
1
Magnetic Resonance Spectroscopy
1
Iodine-131
1
Iodine-123
1
Dexmedetomidine
1
Carboplatin
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Thyroid Neoplasms
×
Carboplatin
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts